Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 20c ; Offers Guidance

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q3 EPS of $0.05, $0.20 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $133.01 million versus the consensus estimate of $130.11 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2025 revenue of $500-510 million, versus the consensus of $506.7 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Crescent Biopharma (CBIO) Reiterated at Buy by Stifel on CR-003/SKB105 Potential
• Deutsche Bank Downgrades L'Oreal SA (OR:FP) (LRLCY) to Sell